MET proto-oncogene amplification ( MET amp) is associated with poor prognosis in gastric or gastroesophageal junction (G/GEJ) cancer. Currently, effective targeted therapies for G/GEJ cancer harboring MET amp remain unavailable, and clinical evidence supporting the use of MET inhibitors in this disease population is limited.
Here we report the results of a phase 2 study of savolitinib, an oral MET inhibitor, in patients with MET amp G/GEJ cancer. This open-label, multicenter, phase 2 trial in China comprised an exploratory phase and a pivotal phase.
Patients with MET amp (gene copy number ≥10 for pivotal phase), locally advanced or metastatic G/GEJ cancer that had progressed following ≥1 (≥2 for pivotal phase) prior lines of systemic therapy received savolitinib orally. The primary endpoint was objective response rate (ORR) by independent review committee in the pivotal phase.
In total, 110 patients were enrolled and received savolitinib, including 45 in the exploratory phase and 65 in the pivotal phase.
Nature Medicine published a clinical update in Research Highlights on 01 Jun 2026.
The item focuses on Savolitinib in MET -amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Review the original article for the full source wording and details.